Ion Beam Applications SA (OTCMKTS:IOBCF) Sees Significant Increase in Short Interest

Ion Beam Applications SA (OTCMKTS:IOBCF) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 63,862 shares, a growth of 390.2% from the July 15th total of 13,027 shares. Based on an average trading volume of 319 shares, the days-to-cover ratio is currently 200.2 days.

Ion Beam Applications Stock Performance

IOBCF opened at $19.00 on Wednesday. The firm’s 50 day moving average is $18.96 and its 200-day moving average is $17.78. Ion Beam Applications has a 52-week low of $11.45 and a 52-week high of $20.10.

Institutional Investors Weigh In On Ion Beam Applications

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC purchased a new position in Ion Beam Applications in the 2nd quarter valued at about $271,000. Ieq Capital LLC acquired a new position in shares of Ion Beam Applications in the second quarter worth about $4,072,000. Allworth Financial LP acquired a new position in shares of Ion Beam Applications in the second quarter worth about $190,000. Vise Technologies Inc. purchased a new position in Ion Beam Applications in the second quarter valued at about $590,000. Finally, Meeder Advisory Services Inc. purchased a new position in Ion Beam Applications in the second quarter valued at about $236,000. Hedge funds and other institutional investors own 14.86% of the company’s stock.

About Ion Beam Applications

Ion Beam Applications (OTCMKTS: IOBCF) is a Belgium-based medical technology company specializing in the development and deployment of particle therapy solutions for cancer treatment. Founded in 1986 and headquartered in Louvain-la-Neuve, the company is best known for its Proteus® line of proton therapy systems, which are designed to deliver precise, high-energy particle beams that target tumors while sparing healthy tissue. IBA oversees the full project lifecycle, from system design and manufacturing to installation, commissioning, and ongoing service support.

In addition to its flagship proton therapy business, IBA operates a diversified portfolio of technologies for medical and industrial applications.